Targeted ovarian cancer therapy not cost-effective: study
Monday, March 7, 2011 - 17:00
in Health & Medicine
An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.